6.9 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | FDA TEMPO Pilot: Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices | U.S. Food and Drug Administration | https://www.fda.gov/medical-devices/digital-health-center-excellence/tempo-digital-health-devices-pilot-frequently-asked-questions | 2025-12-05 | health | article | unprocessed | high |
|
Content
Announcement date: December 5, 2025 (Federal Register notice). Statements of interest opened January 2, 2026.
What it is: FDA's Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot — a voluntary program where FDA exercises enforcement discretion for digital health devices used within CMS's CMMI ACCESS model. This creates the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health devices targeting chronic conditions.
Four CMMI ACCESS clinical use areas (TEMPO targets):
- Early cardio-kidney-metabolic (early CKM): hypertension, dyslipidemia, obesity/overweight with central adiposity marker, prediabetes
- CKM: diabetes, chronic kidney disease, atherosclerotic cardiovascular disease
- Musculoskeletal: chronic musculoskeletal pain
- Behavioral health: depression or anxiety
Hypertension is explicitly in scope (early CKM category).
Enforcement discretion mechanics:
- Manufacturers in TEMPO may deploy software, wearables, sensor-based, or AI-enabled devices in routine care settings
- Must collect and report real-world evidence
- Work toward FDA marketing submission evidence package
- FDA does not enforce applicable regulatory requirements during pilot
Scale: Up to ~10 manufacturers per clinical use area selected. This means ~10 digital health products targeting hypertension can operate under TEMPO. National scale for hypertension management is ~73 million affected adults — so TEMPO covers a research fraction, not a population solution.
Equity dimension: CMS ACCESS model includes a fixed adjustment for rural patients in qualifying tracks. No specific urban food desert or income-stratified equity measure. The ACP (Affordability Connectivity Program) subsidy for internet access was discontinued June 2024, removing the connectivity infrastructure TEMPO-eligible patients in low-income urban settings would need.
Timeline:
- January 2, 2026: Statements of interest open
- ~March 2, 2026: FDA sends follow-up requests to selected manufacturers
- March 2026 onward: Selected manufacturers begin deployment
Legal/regulatory analysis sources: Wilson Sonsini (ACCESS + TEMPO overview), Manatt (two-door entryway), ArentFox (five things to know), McDermott (race for digital health access).
Key mechanism: ACCESS Model CMS reimbursement + TEMPO FDA discretion = first time Medicare will pay for uncleared digital health devices in a real-world evidence collection setting. This creates a genuine market entry pathway that didn't exist before January 2026.
Agent Notes
Why this matters: TEMPO is the regulatory infrastructure that could eventually enable FDA-deregulated digital health to reach Medicare patients with hypertension. The January 2026 FDA CDS guidance + TEMPO + CMS ACCESS model are three interlocking pieces of a new digital health access architecture. If this proves effective, it creates a replication template. BUT: scale is tiny (10 manufacturers, Medicare patients only, research setting) — this is a feasibility pilot, not a population-level deployment.
What surprised me: The explicit inclusion of hypertension in the early CKM category. The FDA is formally acknowledging that hypertension digital health needs a structured pathway — not just the general "enforcement discretion" it provided in the January 2026 CDS guidance. TEMPO is more targeted and more meaningful for the hypertension problem than the general guidance.
What I expected but didn't find: Any equity requirement beyond rural adjustment. The TEMPO pilot applies to CMS ACCESS model participants — these are Medicare patients (65+). The population with the worst hypertension control rates (low-income, food-insecure, working-age) is primarily in Medicaid, not Medicare. OBBBA is systematically removing Medicaid coverage for exactly this population. So TEMPO + OBBBA creates a structural divergence: FDA is creating digital health infrastructure for Medicare hypertension patients while OBBBA removes coverage for Medicaid hypertension patients.
KB connections:
the FDA now separates wellness devices from medical devices based on claims not sensor technology...— January 2026 CDS guidance; TEMPO is the next layer of this deregulatory architectureCMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system...— TEMPO formalizes a similar two-speed system at an earlier stage (pre-clearance vs. cleared)rpm-technology-stack-enables-facility-to-home-care-migration...— TEMPO enables RPM deployment at the infrastructure levelonly-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control...— TEMPO is the institutional response to this failure, but scale limitations mean it can't yet solve it
Extraction hints:
- New claim: "The TEMPO pilot creates the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health hypertension management, but its scale (10 manufacturers, Medicare ACCESS participants only) targets a research population rather than the Medicaid and uninsured populations with the highest hypertension non-control rates"
- The TEMPO + OBBBA structural divergence is a strong claim candidate — it's an institutional contradiction occurring simultaneously
Context: TEMPO and the CMS ACCESS model are designed by CMMI (Center for Medicare & Medicaid Innovation) specifically to generate the real-world evidence that traditional FDA review requires. It's a workaround for the regulatory pathway problem where digital health companies need outcomes data to get clearance, but need clearance to collect outcomes data at scale.
Curator Notes
PRIMARY CONNECTION: the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md
WHY ARCHIVED: Represents a structural escalation of FDA's January 2026 digital health deregulation — from general CDS guidance to a specific real-world evidence collection pathway targeting hypertension. The Medicare/Medicaid structural contradiction with OBBBA is a high-value claim candidate.
EXTRACTION HINT: Extract the TEMPO + OBBBA structural contradiction as a compound claim. Note the Medicare (TEMPO) vs. Medicaid (OBBBA) split — different populations, diverging infrastructure. The extractor should flag this for the broader "access infrastructure deteriorating while delivery infrastructure improves" pattern.